Molecular profiling in gastroesophageal cancer—clinical routine and future perspective

Summary Although several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a limited number of targeted therapies have been introduced in clinical routine. Besides scientific interest, international guidelines...

Full description

Saved in:
Bibliographic Details
Published in:Memo - Magazine of European medical oncology 2020-12, Vol.13 (4), p.440-444
Main Authors: Puhr, Hannah Christina, Ilhan-Mutlu, Aysegül
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Short Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Although several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a limited number of targeted therapies have been introduced in clinical routine. Besides scientific interest, international guidelines recommend investigation of some distinct molecular alterations, which are associated with therapeutic consequences. These are (i) human epidermal growth factor receptor 2 (HER2), (ii) programmed death receptor 1 (PD-L1) and (iii) microsatellite instability (MSI). There are some emerging markers, such as Epstein–Barr virus (EBV), which might also be associated with a favorable response to immunotherapy. These routine and potential markers will be further discussed in the scope of this short review.
ISSN:1865-5041
1865-5076
DOI:10.1007/s12254-019-00534-7